The Shreis Scalene Group of Therapeutic and Diagnostic medical device companies is head-quartered in Montgomery County, MD. Together with the Inventor and Technology partner, Dr. Rajah Vijay Kumar, the Shreis Scalene Group is bringing novel, non-invasive, engineering solutions to human health problems. These include the CYTOTRON® with US-FDA Breakthrough Designation granted for solid tumors of the Breast, Liver and Pancreas (among other solid tumors clinically validated in off-shore clinical studies); tissue regeneration (in musculoskeletal disorders, degenerative respiratory disorders, wound healing etc.); the CELLFORN® for safe, non-invasive cancer drug delivery, and the HAEMOSEIS-256® - a diagnostic cardiovascular disease detection device; for North and South American markets, including Mexico and the Caribbean. Shreis’ mission is to introduce leading-edge platform technologies that will impact the survivorship experience with quality of life, and continue to offer global solutions for safer, patient-centric, affordable healthcare.
Company Details
- Employees
- 9
- Address
- 11516 Darnestown Rd, Gaithersburg,maryland 20878,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- shreis.com
- Keywords
- Madrid.
- HQ
- Gaithersburg, Maryland
Shreis Scalene Group Questions
Shreis Scalene Group's website is shreis.com
Shreis Scalene Group's LinkedIn profile is https://www.linkedin.com/company/shreis-scalene-sciences-llc
Shreis Scalene Group has
9 employees.
View email and phone details for 9
employees at Shreis Scalene Group.
Shreis Scalene Group's industry is
Biotechnology Research
Shreis Scalene Group's top competitors are
Gravity Medical Technology,
Kumar Center,
T.g.medical Inc.,
N.b.medical Inc.,
Pocket Naloxone Corp.,
Scalene Cybernetics Limited,
Edumd, Llc (Milemarker),
Institute Of Aerospace Medicine Indian Air Force - Company,
Cima Capital,
Inheritance Funding Company, Inc..
Shreis Scalene Group's categories are Biotechnology Research
